Thank you.
Ms. Fuller, I'd like to ask you about the issue of the relative weight given to the evidence of improved benefit of medication and other factors, like prices in comparator countries. I would be interested in hearing your comments on how you think that should be weighed by the PMPRB in assessing adequate pricing.